MAE-WEST SCORE Project 2 Clinical
MAE-WEST SCORE 项目 2 临床
基本信息
- 批准号:10198761
- 负责人:
- 金额:$ 73.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAgeAgingAlzheimer&aposs disease related dementiaAngiotensin ReceptorAngiotensin-Converting Enzyme InhibitorsAnti-Inflammatory AgentsBiological AgingBiologyBlood VesselsBrainCardiacCardiologyCell physiologyCenters of Research ExcellenceChronicChronic Kidney FailureChronologyClinicalClinical SciencesClinical TrialsCognitiveCoronaryDataDevelopmentDiagnostic testsDiseaseDisease OutcomeDisease ProgressionEFRACEicosanoidsElderlyEndothelial CellsEndotheliumEnrollmentEpidemiologistEvaluationFDA approvedFailureFemaleFoundationsFunctional disorderFundingGeriatricsGoalsGonadal Steroid HormonesHeartHeart failureHumanImpairmentIndividualInflammationInflammatoryInflammatory ResponseInfrastructureIntervention TrialInvestigationIschemiaKidneyLeadLife Cycle StagesLongevityMagnetic Resonance ImagingMeasuresMediator of activation proteinMedicalMen&aposs RoleMicrovascular DysfunctionMolecularMorbidity - disease rateNational Institute on AgingNatureNephrologyOrganPeripheralPhenotypePhysiologicalPhysiologyPlasmaPlayPopulation AnalysisProcessProspective StudiesPublic HealthRandomizedRenal functionRequest for ApplicationsResearchResourcesRoleSamplingScientific Advances and AccomplishmentsScientistSeveritiesSex DifferencesSpecialized CenterStressStructureTestingUrineVariantWomanWomen&aposs RoleWorkage effectage relatedbasebody systemburden of illnessclinical developmentclinical phenotypeeffective interventionendothelial dysfunctionexperiencefrailtyfunctional statusheart functionimprovedintervention effectkidney dysfunctionmalemenmicrovascular agingpopulation basedpreservationpreventprospectiveresponseretinal imagingsexsexual dimorphismstressorsystemic inflammatory responsetargeted treatmenttonometrytraittranslational scientisttreatment as usualtreatment strategy
项目摘要
Project Abstract – MAE-WEST SCORE Project 2
Over the course of life, chronic stressors contribute to multi-organ aging and dysfunction and, ultimately, the
development of clinical disease. Sex remains a critical determinant of the nature and pace of aging and ultimately
longevity. Among mammalian species, it is even more clear that females fundamentally age differently from
males. With advancing chronologic age in humans, differences in biological aging between women and men
become even more pronounced, culminating in the female predominance for a number of important morbid
disease conditions, including notably Alzheimer’s disease and related dementias (ADRD), heart failure with
preserved ejection fraction (HFpEF), progressive chronic kidney disease (CKD), and in turn systemic frailty.
Mechanisms underlying the female predominance for these major morbidities remains unknown and are not
explained by variations in sex hormones or survival bias. Our preliminary work supports that sexual dimorphism
in inflammatory eicosanoid mediators contribute to sex differences in microvascular dysfunction and, in turn, to
sex differences in age-related multi-organ disease, including for ADRD, HFpEF and CKD. Elucidating a common
pathophysiologic basis for the female predominance of ADRD, HFpEF, and CKD holds the key to effective
interventions for reducing the excess burden of age-related disease in women. Motivated our findings and the
critical need to understand the determinants and drivers of sex differences in major age-related disease
outcomes, we propose to establish the Microvascular Aging and Eicosanoids – Women’s Evaluation of Systemic
aging Tenacity (MAE-WEST) (“You are never too old to become younger!”) Specialized Center of Research
Excellence (SCORE) on Sex Differences, in response to NIH RFA-OD-19-013. Our goal is to form a robust and
sustainable structure of academic activities centered on systematically interrogating sex differences in the
relationship among eicosanoids, microvascular dysfunction, and age-related end-organ disease, with an initial
focus on the microvascular aging effects on brain, heart, and kidney function. This goal will be achieved by an
outstanding collaborative team of clinician-scientists (with expertise in geriatrics, cardiology, and nephrology),
epidemiologists, basic and translational scientists, analytical chemists, biostatisticians, and bioinformaticians.
Leveraging our collective experience, resources, and infrastructure, we will advance the scientific enterprise
through 3 foundational projects aligned and complementary yet independent. Project 2 will determine the sex-
specific association of eicosanoids with microvascular physiology in women and men and the role of
FDA approved agents in modulation of total microvascular disease burden. In a sample of women and
men with deep clinical phenotyping, this clinical science project will examine sex differences in the relations of
eicosanoids with the co-occurrence of microvascular aging traits across major organ systems (brain, heart,
kidney, systemic frailty) and evaluate the effects of intensive medical treatment with high-intensity statin plus
ACEi or ARB therapy on both eicosanoid profiles and total microvascular disease burden.
项目摘要-MAE-WEST评分项目2
在生命过程中,慢性应激源会导致多器官衰老和功能障碍,最终导致
临床疾病的发展。性别仍然是衰老的性质和速度的关键决定因素,并最终
长寿。在哺乳动物物种中,更明显的是,女性的年龄与
男性。随着人类年龄的增加,女性和男性在生物衰老方面的差异
变得更加明显,最终导致女性占主导地位的一些重要病态
疾病状况,包括阿尔茨海默病和相关痴呆症(ADRD),心力衰竭和
保留射血分数(HFpEF)、进展性慢性肾脏疾病(CKD),进而导致全身虚弱。
这些重大疾病以女性为主的机制仍不清楚,也不是
可以用性激素的变化或生存偏见来解释。我们的初步工作支持这种性别二型性
在炎症性二十烷类介质中,微血管功能障碍的性别差异,进而导致
年龄相关多器官疾病的性别差异,包括ADRD、HFpEF和CKD。阐明一个共同之处
ADRD、HFpEF和CKD以女性为主的病理生理学基础是有效的关键
减轻妇女年龄相关疾病过重负担的干预措施。激发了我们的发现和
迫切需要了解重大年龄相关疾病性别差异的决定因素和驱动因素
结果,我们建议建立微血管老化和二十烷类化合物-女性全身性评估
变老的坚韧(Mae-West)(“活到老,活到老!”)专业研究中心
性别差异优秀(得分),回应NIH RFA-OD-19-013。我们的目标是形成一个强大和
学术活动的可持续结构以系统地询问性别差异为中心
二十烷类化合物、微血管功能障碍和年龄相关的终末器官疾病之间的关系,最初的
重点研究微血管老化对脑、心、肾功能的影响。这一目标将通过一个
出色的临床医生-科学家协作团队(在老年病学、心脏病学和肾脏学方面具有专业知识),
流行病学家、基础科学家和翻译科学家、分析化学家、生物统计学家和生物信息学家。
利用我们的集体经验、资源和基础设施,我们将推动科学事业
通过3个基础项目协调一致、互补但又独立。项目2将决定性别-
二十烷基类化合物与男性和女性微血管生理学的特异性关联及其作用
FDA批准了调节总微血管疾病负担的药物。在一组女性和
临床表型较深的男性,这一临床科学项目将研究性别差异与
二十烷类化合物与主要器官系统(脑、心脏、
肾脏、全身虚弱),并评估高强度他汀类药物加强化治疗的效果
血管紧张素转换酶抑制剂或血管紧张素转换酶治疗对二十烷类药物和总的微血管疾病负担的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cathleen Noel Bairey Merz其他文献
Cathleen Noel Bairey Merz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cathleen Noel Bairey Merz', 18)}}的其他基金
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)
微血管老化和类二十烷酸 - 女性全身老化韧性评估 (MAE-WEST)(“你永远不会太老,变得更年轻!”)卓越研究专业中心 (SCORE)
- 批准号:
10198755 - 财政年份:2020
- 资助金额:
$ 73.29万 - 项目类别:
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)
微血管老化和类二十烷酸 - 女性全身老化韧性评估 (MAE-WEST)(“你永远不会太老,变得更年轻!”)卓越研究专业中心 (SCORE)
- 批准号:
10450755 - 财政年份:2020
- 资助金额:
$ 73.29万 - 项目类别:
MAE-WEST SCORE Leadership Administrative Core
MAE-WEST SCORE 领导力行政核心
- 批准号:
10450756 - 财政年份:2020
- 资助金额:
$ 73.29万 - 项目类别:
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)
微血管老化和类二十烷酸 - 女性全身老化韧性评估 (MAE-WEST)(“你永远不会太老,变得更年轻!”)卓越研究专业中心 (SCORE)
- 批准号:
10817498 - 财政年份:2020
- 资助金额:
$ 73.29万 - 项目类别:
MAE-WEST SCORE Leadership Administrative Core
MAE-WEST SCORE 领导力行政核心
- 批准号:
10198756 - 财政年份:2020
- 资助金额:
$ 73.29万 - 项目类别:
Women's Ischemia Syndrome Evaluation (WISE) - Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)
女性缺血综合征评估 (WISE) - 冠状动脉微血管功能障碍导致射血分数保留 (HFpEF) 的先兆心力衰竭的机制
- 批准号:
9922714 - 财政年份:2019
- 资助金额:
$ 73.29万 - 项目类别:
Women's Ischemia Syndrome Evaluation (WISE) - Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)
女性缺血综合征评估 (WISE) - 冠状动脉微血管功能障碍导致射血分数保留 (HFpEF) 的先兆心力衰竭的机制
- 批准号:
10576287 - 财政年份:2019
- 资助金额:
$ 73.29万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
- 批准号:
23K07844 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
- 批准号:
22KJ2960 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
- 批准号:
23KK0156 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
- 批准号:
10677409 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
- 批准号:
497927 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
- 批准号:
10836835 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
- 批准号:
478877 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Operating Grants
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
- 批准号:
23K06378 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
- 批准号:
23K10845 - 财政年份:2023
- 资助金额:
$ 73.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)